Investment Rating - The report assigns an "Accumulate" rating to the company [6][32]. Core Insights - The company is actively developing non-housing businesses to mitigate cyclical risks and is focusing on cost reduction and efficiency improvements while enhancing shareholder returns [2][10]. - The company is a leading integrated online and offline real estate transaction platform, benefiting from market share advantages for long-term growth [32]. Financial Performance Summary - In 2025, the company's total transaction volume was 31,833 billion RMB, a decrease of 5.0% year-on-year, while net revenue increased by 1.2% to 946 billion RMB [15][21]. - Operating expenses for 2025 were 181 billion RMB, down 5.6% year-on-year, leading to a reduction in the proportion of operating expenses to net revenue by 1.4 percentage points [15][21]. - The net profit for 2025 was 29.91 billion RMB, a decline of 26.7%, with adjusted net profit at 50.17 billion RMB, down 30.4% [15][21]. Business Segment Performance - The company's existing housing business generated net revenue of 25 billion RMB in 2025, a decrease of 11.3%, with total transaction volume at 21,515 billion RMB, down 4.2% [25][28]. - The new housing business reported net revenue of 30.6 billion RMB, a decline of 9.1%, with total transaction volume of 8,909 billion RMB, down 8.2% [28][30]. - The home decoration and furniture business achieved net revenue of 15.4 billion RMB, a year-on-year increase of 4.4% [30]. Shareholder Returns - In 2025, the company spent approximately 921 million USD on share repurchase programs, with total shareholder returns reaching about 1.2 billion USD, an increase of over 9% year-on-year [16][30].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 725 HKD, indicating an 11% upside potential from the current price [4]. Core Insights - The company exceeded expectations for 2025, achieving a revenue of 423.7 billion RMB, a 17% year-on-year increase, and a net profit of 72.2 billion RMB, up 42.3% year-on-year [2]. - The market share of the company's power batteries increased, with a revenue of 316.5 billion RMB from power battery systems, reflecting a 25.1% year-on-year growth, and a sales volume of 541 GWh, up 41.9% year-on-year [2]. - The company also reported a steady growth in energy storage batteries, with a revenue of 62.4 billion RMB, an 8.99% increase year-on-year, and a global market share of 30.4% [3]. - Significant investment in R&D was noted, with expenses reaching 22.1 billion RMB, a 19.0% increase year-on-year, focusing on new battery technologies and solutions [3]. Financial Performance - The company reported a cash and cash equivalents balance of 299.9 billion RMB at the end of 2025 [2]. - The gross margin improved to 26.3% in 2025, supported by a capacity utilization rate of 96.9% [2]. - Forecasted revenues for 2026-2028 are projected at 579.2 billion RMB, 723.1 billion RMB, and 876.7 billion RMB respectively, with net profits expected to reach 930 billion RMB, 1,165 billion RMB, and 1,400 billion RMB [4].

Investment Rating - The report initiates coverage of Midea Group H shares with a "Buy" rating and sets a target price of HKD 109.42, based on a 14.5x PE for 2026 [1][7]. Core Insights - Midea Group is transitioning from a traditional home appliance leader to a technology-driven industrial group, leveraging its full supply chain manufacturing capabilities and digital channels to drive growth [1][4]. - The ToB (business-to-business) segment is expected to be a significant growth driver, with a projected CAGR of 14% from 2025 to 2027, increasing its revenue contribution from 27.2% to 29.3% [1][3]. - The company anticipates a net profit CAGR of approximately 12.6% from 2025 to 2027, outperforming industry peers [1][5]. Summary by Sections Investment Rating - Midea Group is rated as "Buy" with a target price of HKD 109.42 based on a 14.5x PE for 2026 [1][7]. Business Overview - Midea has established a four-business matrix: smart home, new energy/industrial technology, smart buildings, and robotics, combining hard manufacturing capabilities with soft management efficiencies [2][18]. - The company’s ToB business is gaining traction, with revenue share expected to rise to nearly 26% by mid-2025, driven by its existing capabilities in motors, compressors, and automation [3][17]. Financial Projections - Midea's projected net profits for 2025, 2026, and 2027 are RMB 44.87 billion, RMB 49.80 billion, and RMB 55.07 billion, respectively, with corresponding EPS of RMB 5.90, RMB 6.55, and RMB 7.24 [5][11]. - The company is expected to maintain a strong cash flow with a dividend payout ratio of 69.3%, indicating a potential dividend yield of over 5% [17][18]. Competitive Advantages - Midea's long-term competitive advantage is built on a combination of hard manufacturing capabilities, soft management strengths, and integrated industry solutions through its ToB business [18]. - The company’s robust R&D investment, projected to exceed RMB 15 billion in 2024, supports its product advantages and governance structure [18].

Investment Rating - The investment rating for the company is "Buy" [1] Core Insights - The report indicates that the company's overseas sales of Furuzanlin have shown robust growth, while domestic sales of core products are recovering. The overall sales trend is improving, with a projected revenue increase for 2026 [4][7] - The company achieved a total revenue of $549 million in 2025, a decrease of 12.96% year-on-year, with a significant increase in net profit attributed to the sale of non-core businesses [5][6][8] - The company is focusing on innovative drug development and has a promising pipeline, including the ATTC platform, which is expected to drive long-term growth [8][10] Financial Performance - In 2025, the company reported total revenue of $549 million, with a year-on-year decline of 12.96%. The oncology/immunology business generated $290 million, down 21% year-on-year [5][6] - The net profit attributable to the parent company was $457 million, a significant increase from $40 million in 2024, largely due to the sale of Shanghai Hutchison Pharmaceuticals [8] - The company expects total revenue for 2026 to be between $330 million and $450 million, reflecting a growth of 14% to 55% year-on-year [7][8] Product Pipeline and Clinical Development - The company has several key products in its pipeline, including Furuzanlin, which is expected to penetrate global markets and expand treatment indications [9] - The ATTC platform is showing clinical value and potential for international expansion, with multiple candidates entering clinical trials [8][9] - The company anticipates significant clinical results from ongoing studies, including the SAFFRON and SANOVO trials, which are expected to read out in 2026 [8][9]

Investment Rating - The report maintains a "BUY" rating for Chuangxin Industries with an unchanged target price of HK$32, indicating a potential upside of 17% from the current price of HK$27.34 [3][4]. Core Insights - Chuangxin Industries reported a net profit growth of 33% year-on-year to RMB2.73 billion in 2025, which is 5% above expectations but 2% below Bloomberg consensus [1]. - The company proposed a final dividend of HK$0.77 per share, representing a payout ratio of approximately 54%, which exceeded prior expectations [1]. - Chuangxin announced two acquisitions: (1) acquiring the remaining 41.5% interest in Shandong Chuangyuan for RMB526 million, and (2) acquiring a coal mining business for RMB1 billion. The alumina exposure increase is viewed positively, while the coal mining acquisition is seen as slightly negative due to the company's shift towards renewable energy [1][9]. Financial Performance Summary - Revenue for 2025 grew by 23.2% year-on-year to RMB18.68 billion, driven by a 6% increase in aluminium and a 139% increase in alumina and alumina hydroxide [9][10]. - The gross margin for the aluminium business expanded by 3.3 percentage points year-on-year to 30.2%, while the blended gross margin narrowed by 3.4 percentage points to 24.8% due to higher low-margin alumina revenue [9][10]. - The net debt to equity ratio improved significantly to 56% by the end of 2025, down from 466% at the end of 2024, aided by strong earnings and an IPO in Hong Kong [9]. Earnings Forecast - The adjusted net profit is projected to reach RMB4.54 billion in 2026, with a growth rate of 66.4% compared to 2025 [2][15]. - Revenue is expected to continue growing, with estimates of RMB19.67 billion in 2026 and RMB20.12 billion in 2028, reflecting a gradual slowdown in growth rates [2][15]. Valuation Metrics - The price-to-earnings (P/E) ratio is projected to decrease from 13.6 in 2025 to 9.8 by 2028, indicating an attractive valuation as earnings grow [2][15]. - The price-to-book (P/B) ratio is expected to decline from 5.2 in 2025 to 2.3 by 2028, further supporting the investment case [2][15].

Investment Rating - The report maintains a "Buy" investment rating for the company [3][5]. Core Insights - The company achieved a total revenue of 2.913 billion RMB in 2025, representing a year-on-year growth of 30.01%. The net profit attributable to shareholders reached 634 million RMB, a significant increase of 258.02% year-on-year. Adjusted net profit was 675 million RMB, up by 15.5% [1][3]. - Strong overseas growth was noted, with revenue from domestic and international markets at 2.59 billion RMB and 320 million RMB respectively, reflecting growth rates of 19% and 397%. In specific overseas markets, revenue from North America and Asia (excluding China) surged by 804% and 238% respectively [1][2]. - The company launched 29 commercialized IPs by the end of 2025, with the top four best-selling IPs generating revenues of 951 million RMB, 815 million RMB, 331 million RMB, and 264 million RMB respectively [2]. - The gross margin for 2025 was reported at 46.82%, a decrease of 5.78 percentage points year-on-year. The net profit margin improved by 39.52 percentage points to 21.75% [2]. Financial Summary - The company is projected to achieve net profits of 831 million RMB, 1.068 billion RMB, and 1.352 billion RMB for the years 2026, 2027, and 2028, with respective growth rates of 31.1%, 28.6%, and 26.6% [3][4]. - The earnings per share (EPS) for 2025 is estimated at 2.54 RMB, with projections of 3.33 RMB, 4.29 RMB, and 5.42 RMB for the following years [4]. - The total revenue is expected to grow from 2.913 billion RMB in 2025 to 6.108 billion RMB by 2028, with a compound annual growth rate (CAGR) of approximately 26% [4].

Investment Rating - The report maintains a "Buy" investment rating for the company [3][5]. Core Insights - The company achieved a total revenue of 2.913 billion RMB in 2025, representing a year-on-year growth of 30.01%. The net profit attributable to shareholders reached 634 million RMB, a significant increase of 258.02% year-on-year [1]. - Strong overseas growth was noted, with revenue from international markets reaching 320 million RMB, a staggering increase of 397% year-on-year. North America and Asia (excluding China) saw revenue growth of 804% and 238%, respectively [1][2]. - The company has successfully commercialized 29 IPs by the end of 2025, with the top four best-selling IPs generating revenues of 951 million RMB, 815 million RMB, 331 million RMB, and 264 million RMB, respectively [2]. - The adjusted net profit for 2025 was 675 million RMB, reflecting a year-on-year increase of 15.5% [1]. Financial Summary - Revenue and profit forecasts for 2026-2028 are projected at 8.31 billion RMB, 10.68 billion RMB, and 13.52 billion RMB, with respective growth rates of 31.1%, 28.6%, and 26.6% [3]. - The company's gross margin for 2025 was reported at 46.82%, a decrease of 5.78 percentage points year-on-year. The net profit margin improved to 21.75%, an increase of 39.52 percentage points year-on-year [2]. - The company’s earnings per share (EPS) for 2025 was 2.54 RMB, with projections of 3.33 RMB, 4.29 RMB, and 5.42 RMB for 2026, 2027, and 2028, respectively [4]. Market Position - The company operates in the entertainment products industry, with a market capitalization of approximately 16.59 billion HKD and a total share count of 249.25 million [5]. - The stock price as of March 16 was 66.55 HKD, with a P/E ratio of 23.0 for 2025, expected to decrease to 10.8 by 2028 [4][5].

Investment Rating - The report maintains a "Buy" rating for Zai Lab (09688) [4][16] Core Insights - The report highlights a slowdown in commercialization growth while noting a rich pipeline of innovative products that could catalyze future growth [4][9] - Zai Lab's revenue for 2025 is projected to grow by 15% year-on-year, reaching USD 460 million, with a reduction in net losses from USD 257 million in 2024 to USD 176 million in 2025 [12][19] - The company has a strong cash position of approximately USD 790 million as of the end of 2025, which supports ongoing research and development efforts [12][19] Financial Performance Summary - In 2025, total revenue reached USD 460 million, with product revenue contributing USD 457 million, marking a 15% increase year-on-year [12][13] - R&D expenses decreased by 6% year-on-year to USD 221 million, with the R&D expense ratio dropping from 59% in 2024 to 48% in 2025 [12][19] - The company expects to launch multiple new products in 2026, including KarXT and TIVDAK, which have received or are expected to receive regulatory approvals [14][15] Sales Growth and Product Performance - Significant sales growth was observed in key products, with XACDURO sales increasing by 593% to USD 23 million and NUZYRA sales rising by 41% to USD 61 million in 2025 [13][8] - The report notes that ZEJULA's sales remained stable at USD 189 million due to changes in the competitive landscape of the PARP market [13][8] Pipeline Catalysts - The report identifies several upcoming catalysts in 2026, including data readouts for various clinical trials and the initiation of global studies for new treatments [15][9] - Key products in the pipeline include Zoci, Efgartigimod, and Povetacicept, which are expected to provide significant data updates in the near future [15][9]

Investment Rating - The report maintains a "Buy" rating for Leap Motor [1][2] Core Insights - Leap Motor achieved a net profit of 540 million RMB in 2025, becoming the second domestic new car manufacturer to achieve annual profitability [2] - The company is expected to continue its growth trajectory with significant revenue increases projected for the coming years, driven by new vehicle launches and international market expansion [2][8] Financial Summary - Total revenue for 2025 reached 64.732 billion RMB, representing a year-on-year increase of 101% [3] - The net profit for 2025 was 540 million RMB, marking a turnaround from a loss of 2.821 billion RMB in 2024 [3] - The gross profit margin for 2025 was 14.5%, an increase of 6.1 percentage points year-on-year, with a quarterly gross margin of 15.0% in Q4 2025 [8] - The company delivered 597,000 vehicles in 2025, doubling the delivery volume compared to the previous year [8] Market Position and Future Outlook - Leap Motor's international expansion is accelerating, with 67,000 vehicles exported in 2025 and entry into 40 countries and regions [8] - The company plans to launch new models in 2026, including the A10 SUV and two flagship models in the D series, which are expected to enhance its product lineup and drive sales growth [8] - The report projects net profits of 4.839 billion RMB, 7.739 billion RMB, and 9.523 billion RMB for 2026, 2027, and 2028, respectively [8]

Investment Rating - The investment rating for Sinopec Engineering (02386.HK) is "Buy" with a current price of HKD 6.23 and a target value of HKD 8.12 [6]. Core Views - The report highlights that the company maintains its special dividend and keeps the total dividend unchanged, reflecting confidence in its financial stability. The expected recovery in profit margins is anticipated as project execution progresses [6][10]. - The company reported a revenue of RMB 70.1 billion for 2025, a year-on-year increase of 9.2%, while the net profit attributable to shareholders decreased by 27.1% to RMB 1.798 billion due to declining gross margins and interest income [6][10]. - The report indicates that the decline in gross margin to 7.4% in 2025 was primarily due to underperformance in two Saudi projects, impacting the construction gross margin significantly [6][10]. Financial Forecast - Revenue projections for the upcoming years are as follows: - 2024: RMB 64.198 billion - 2025: RMB 70.074 billion - 2026: RMB 77.026 billion - 2027: RMB 84.014 billion - 2028: RMB 90.757 billion - The growth rates for these years are projected at 13.9%, 9.2%, 9.9%, 9.1%, and 8.0% respectively [2]. - The expected EBITDA figures are: - 2024: RMB 2.779 billion - 2025: RMB 2.361 billion - 2026: RMB 2.867 billion - 2027: RMB 3.293 billion - 2028: RMB 3.458 billion [2]. - The net profit attributable to shareholders is forecasted to recover to RMB 2.291 billion in 2026, RMB 2.539 billion in 2027, and RMB 2.821 billion in 2028, with growth rates of 27.5%, 10.8%, and 11.1% respectively [2][10]. Dividend Policy - The company declared a special dividend of RMB 0.094 per share, maintaining the total dividend at RMB 0.358 per share for 2025, resulting in a dividend payout ratio of 88% and a dividend yield of 6.2% as of March 16 [6][10].